Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Diabetes threatens the eyesight of many unsuspecting Americans

Diabetes threatens the eyesight of many unsuspecting Americans

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

Arena's NDA receives Complete Response Letter for lorcaserin

Arena's NDA receives Complete Response Letter for lorcaserin

Diabetes on the rise in Scotland

Diabetes on the rise in Scotland

FDA issues complete response letter for BYDUREON NDA

FDA issues complete response letter for BYDUREON NDA

Study shows impaired insulin sensitivity may serve as mediator between obesity and cognitive decline

Study shows impaired insulin sensitivity may serve as mediator between obesity and cognitive decline

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Type 2 diabetes and insulin use associated with CRC risk in men, but not women

Type 2 diabetes and insulin use associated with CRC risk in men, but not women

Study reinforces need for physicians to screen obstructive sleep apnea prior to surgery

Study reinforces need for physicians to screen obstructive sleep apnea prior to surgery

FDA approves Gamunex-C for primary immunodeficiency treatment

FDA approves Gamunex-C for primary immunodeficiency treatment

AACE publishes consensus statement for continuous glucose monitoring

AACE publishes consensus statement for continuous glucose monitoring

Bariatric surgery reduces healthcare costs for morbidly obese diabetics

Bariatric surgery reduces healthcare costs for morbidly obese diabetics

Metabolic screening before conception predicts development of diabetes in subsequent pregnancy

Metabolic screening before conception predicts development of diabetes in subsequent pregnancy

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Adeona announces five scientific publications on Alzheimer's disease and cognitive decline

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Endocrine Society urges physicians to apply new insights into the role of beta-cells in type 2 diabetes

Endocrine Society urges physicians to apply new insights into the role of beta-cells in type 2 diabetes

Gymnemic acid nanocrystals could help develop soluble drug compounds

Gymnemic acid nanocrystals could help develop soluble drug compounds

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Novo Nordisk announces $73M expansion of Clayton insulin delivery systems manufacturing facility

Novo Nordisk announces $73M expansion of Clayton insulin delivery systems manufacturing facility

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.